Myogenes Clozapine Test: Revolutionising Treatment-Resistant Schizophrenia Management Through Personalised Genetic Analysis

The Myogenes Clozapine Test is a groundbreaking innovation aimed at revolutionising the management of treatment-resistant schizophrenia (TRS), which affects approximately 30% of schizophrenia cases globally. This comprehensive genetic analysis tool addresses the ineffective trial-and-error approach currently used in TRS treatment.

Key innovations include: 1. Clozapine-specific genetic analysis 2. Agranulocytosis risk assessment 3. Personalised dosage optimization 4. Benign Ethnic Neutropenia (BEN) status identification

Unlike existing generalised tests, our solution is tailored specifically for clozapine treatment in TRS. The BEN status identification feature can reduce unnecessary treatment discontinuation for 80% of people of African descent, addressing a significant gap in current protocols.

The test has the potential to increase treatment success rates from 66% to 80%, benefiting TRS patients and healthcare providers. A business impact model projects £1.78 billion in NHS savings over three years, with 44,878 fewer hospital admissions and 2,115,791 fewer bed days.

Our progress includes a successful 18-participant clinical study, pilot projects with five NHS trusts involving 200 patients, and established relationships with high-capacity labs. An academic paper from our North Hampton trial has been published in the Journal of Psychopharmacology, with another from SLAM NHS trust forthcoming. Central North West London NHS Trust is incorporating our test into their protocol for patients resistant to two antipsychotics.

This project phase will focus on: 1. Identifying new genetic markers for clozapine response and side effects 2. Refining dosage recommendations

3. Extending gene profiling for drug-drug interactions Our innovation addresses equality challenges by preventing unnecessary treatment discontinuation in ethnic minority patients due to BEN misidentification.